drugset
drugset / Trial / NCT05123196

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

NCT05123196 ↗

Phase 2 Completed 156 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of MT-8554, compared to placebo, in subjects with painful diabetic peripheral neuropathy.

Timeline

Start
2021-11-16
Primary completion
2022-11-01
Completion
2022-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule — Oral

Indications

diabetic polyneuropathy